EPGNF Epigenomics AG

Epigenomics AG, a molecular diagnostics company, focuses on developing and commercializing in vitro diagnostic tests for the screening, early detection, and diagnosis of cancer in Germany and internationally. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer, which relies on its proprietary DNA methylation biomarker, Septin9. The company also offers Epi proLung, a confirmatory test that aids in the diagnosis of lung cancer. Its development pipeline also contains tests for screening, monitoring, diagnosis, and prognosis assessment in colorectal and lung cancer. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.

Note: This is not a U.S. company, but they cross-list their shares on the U.S. over-the-counter market - see the related symbol GF:ECX.

$0.70    OTCQX
As of 01/14/2022     OTCMarkets


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Unknown
Industry:  Diagnostics & Research
Index country:  Germany
Country of incorporation:  
IPO date:  09/15/2004
Outstanding shares:  11,823,227
Average volume:  195
Market cap:   $8,309,364
Current dividend yield:  0.00%
Sedol:      
Valuation   (See tab for details)
PE ratio:   -2.53
PB ratio:   0.35
PS ratio:   1.15
Return on equity:   -13.49%
Net income %:   -51.70%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy